Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent
MetadataShow full item record
CitationPantziarka, Pan, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, and Vikas P Sukhatme. 2014. “Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent.” ecancermedicalscience 8 (1): 485. doi:10.3332/ecancer.2014.485. http://dx.doi.org/10.3332/ecancer.2014.485.
AbstractCimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:13581211
- HMS Scholarly Articles